DOK2 inhibits EGFR-mutated lung adenocarcinoma.

about

Expression and significance of DOK2 in colorectal cancer.Co-expression and significance of Dok2 and Ras p21 protein activator 1 in breast cancer.Region-Specific Dok2 Overexpression Associates with Poor Prognosis in Human Astrocytoma.

P2860

Q42247530-1B7CA592-5E52-4E49-B24B-61B4DECBA406 Q47143266-DE8EAC90-1DAB-4FC8-A8E8-903F26944EFF Q48395366-9305D593-3E95-4269-8327-672D9ED5ADCD

P2860

DOK2 inhibits EGFR-mutated lung adenocarcinoma.

Item

http://www.wikidata.org/entity/Q35047411

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

DOK2 inhibits EGFR-mutated lung adenocarcinoma.

@en

type

Item

label

DOK2 inhibits EGFR-mutated lung adenocarcinoma.

@en

prefLabel

DOK2 inhibits EGFR-mutated lung adenocarcinoma.

@en

P1476

DOK2 inhibits EGFR-mutated lung adenocarcinoma.

@en

P2093

Alice H Berger

http://www.w3.org/2001/XMLSchema#string

Barry S Taylor

http://www.w3.org/2001/XMLSchema#string

Justyna A Janas

http://www.w3.org/2001/XMLSchema#string

Linda Van Aelst

http://www.w3.org/2001/XMLSchema#string

Masaru Niki

http://www.w3.org/2001/XMLSchema#string

Roderick T Bronson

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins

Dok-R mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and Csk.

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Recruitment of Dok-R to the EGF receptor through its PTB domain is required for attenuation of Erk MAP kinase activation

P304

e79526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0079526

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258768536

http://www.w3.org/2001/XMLSchema#string

P698

24255704

http://www.w3.org/2001/XMLSchema#string

P932

3821857

http://www.w3.org/2001/XMLSchema#string

DOK2 inhibits EGFR-mutated lung adenocarcinoma.

about

P2860

P2860

DOK2 inhibits EGFR-mutated lung adenocarcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P932